Abivax SAvsEli Lilly and Company

ABVX and LLY stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

Abivax SA (ABVX) has a market value of $5.7B and Eli Lilly and Company (LLY) $1.27T. Over the last year, with dividends, ABVX moved -35.2% and LLY +29.1%. Dividend yield: ABVX none, LLY 0.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABVX$5.7B

    LLY$1.27T

    LLY is 221 times ABVX

  • Revenue, 12 months

    ABVX–

    LLY$86.5B

  • Net income, 12 months

    ABVX-$394M

    LLY$27.6B

  • Operating margin

    ABVX–

    LLY–

  • ROIC

    ABVX-42.7%

    LLY35.5%

    78.2 points apart

  • P/E

    ABVX–

    LLY46.1

  • Dividend yield

    ABVX0.0%

    LLY0.5%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABVX+564.3%

LLY+129.9%

05001000202420252026
Returns by period
PeriodABVXWith dividendsLLYWith dividends
1 year since November 19, 2025-35.2%Price -35.2%+29.1%Price +28.3%
3 years since November 20, 2023+564.2%+88.0% a yearPrice +564.2%+130.0%+32.0% a yearPrice +125.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABVXAbivax SALLYEli Lilly and Company

Valuation

ABVXLLY
Valuation
Price$73.20$1,347.11
Market value$5.7B$1.27T
Enterprise value (EV)$5.1B$1.32T
P/E–46.1
P/E, 5-year median–49.9
P/B10.831.6
EV/EBIT–37.8
Free cash flow yield–1.6%

Results and growth

ABVXLLY
Results and growth
Revenue, 12 months–$86.5B
Net income, 12 months-$394M$27.6B
Free cash flow, 12 months-$189M$19.7B
Earnings per share, 12 months-$5.67$30.81
Revenue growth, year on year–44.7%
Revenue growth a year, past–+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

ABVXLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin––
Net margin–31.9%
ROIC-42.7%35.5%
ROE-73.8%88.6%

Balance sheet

ABVXLLY
Balance sheet
Cash$606M$4.9B
Total debt$2.2M$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

ABVXLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABVX or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Abivax SA or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.27T) is about 221.1 times Abivax SA ($5.7B), at today's prices.

How did ABVX and LLY stock do over the last 3 years?

Since November 20, 2023, ABVX's price moved +564.2% and LLY's +125.4%. With dividends: ABVX +564.2% (+88.0% a year), LLY +130.0% (+32.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABVX or LLY?

The dividend yield at today's price is none for Abivax SA and 0.47% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which is the better investment, Abivax SA or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.